Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.53 |
| ▸ | CASR | P41180 | 4/20 | 0.49 |
| ▸ | CTSA | P10619 | 7/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16712950 | 0.93 | CTSA (0.48) | ERN1CASRCTSADHFRHDAC4 | |
| SCHEMBL18084776 | 0.91 | CASR (0.46) | ERN1CASRCTSADHFRHDAC4 | |
| SCHEMBL16712942 | 0.91 | BACE1 (0.46) | ERN1CASRCTSAHDAC4HDAC8 | |
| SCHEMBL16712954 | 0.90 | ERN1 (0.51) | ERN1CASRCTSAFYN | |
| SCHEMBL11951612 | 0.89 | CASR (0.53) | ERN1CASRCTSAHDAC4HDAC8 | |
| SCHEMBL8940819 | 0.88 | HDAC4 (0.50) | ERN1CASRHDAC4HDAC8FYN | |
| SCHEMBL9254425 | 0.87 | ERN1 (0.49) | ERN1CASRCTSADHFR | |
| SCHEMBL23525668 | 0.86 | ERN1 (0.48) | ERN1CASRDHFRFYNLMNA | |
| SCHEMBL27316386 | 0.86 | SMN1; SMN2 (0.51) | ERN1CASRCTSAFYN | |
| SCHEMBL16710318 | 0.82 | PDE4B (0.49) | CTSAHDAC4HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| WO-2011007819-A1 | PHARMACEUTICAL PRODUCT CONTAINING LACTAM OR BENZENE SULFONAMIDE COMPOUND | 塩野義製薬株式会社 (JP) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | ERN1 3670/4885CASR 2536/4885CTSA 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.